Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

In the EMPEROR trial, children with a confirmed variant in the SCN1A gene not associated with gain-of-function mutations will receive zorevunersen or a placebo.

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.